Stonebridge Capital Advisors LLC acquired a new stake in Abbott Laboratories (NYSE:ABT) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,282 shares of the healthcare product maker’s stock, valued at approximately $235,000.

A number of other institutional investors have also recently made changes to their positions in ABT. Cypress Capital Management LLC WY boosted its position in shares of Abbott Laboratories by 37.9% in the first quarter. Cypress Capital Management LLC WY now owns 2,531 shares of the healthcare product maker’s stock valued at $112,000 after buying an additional 696 shares during the period. Feltz Wealth PLAN Inc. purchased a new position in shares of Abbott Laboratories during the first quarter valued at about $112,000. First Command Financial Services Inc. boosted its position in shares of Abbott Laboratories by 10.2% in the first quarter. First Command Financial Services Inc. now owns 2,787 shares of the healthcare product maker’s stock valued at $124,000 after buying an additional 257 shares during the period. Atwood & Palmer Inc. boosted its position in shares of Abbott Laboratories by 157.5% in the first quarter. Atwood & Palmer Inc. now owns 3,270 shares of the healthcare product maker’s stock valued at $145,000 after buying an additional 2,000 shares during the period. Finally, Independent Portfolio Consultants Inc. boosted its position in shares of Abbott Laboratories by 9.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 3,420 shares of the healthcare product maker’s stock valued at $152,000 after buying an additional 292 shares during the period. Hedge funds and other institutional investors own 70.86% of the company’s stock.

Abbott Laboratories (NYSE ABT) traded up 0.092% during mid-day trading on Tuesday, hitting $49.125. The stock had a trading volume of 846,651 shares. The stock’s 50 day moving average price is $49.09 and its 200 day moving average price is $45.79. The firm has a market capitalization of $85.35 billion, a price-to-earnings ratio of 68.803 and a beta of 1.07. Abbott Laboratories has a one year low of $37.38 and a one year high of $51.13.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same quarter last year, the company earned $0.55 EPS. The company’s revenue was up 24.5% on a year-over-year basis. Analysts forecast that Abbott Laboratories will post $2.49 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be paid a dividend of $0.265 per share. The ex-dividend date is Wednesday, July 12th. This represents a $1.06 dividend on an annualized basis and a yield of 2.16%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 149.30%.

TRADEMARK VIOLATION WARNING: “Stonebridge Capital Advisors LLC Acquires Shares of 5,282 Abbott Laboratories (ABT)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.watchlistnews.com/stonebridge-capital-advisors-llc-acquires-shares-of-5282-abbott-laboratories-abt/1491198.html.

A number of equities research analysts have issued reports on the company. UBS AG reiterated a “neutral” rating and issued a $41.00 target price on shares of Abbott Laboratories in a research note on Tuesday, April 18th. BidaskClub cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, August 6th. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus restated a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 21st. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Abbott Laboratories presently has a consensus rating of “Buy” and a consensus target price of $52.08.

In related news, insider Hubert L. Allen sold 4,600 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $50.79, for a total transaction of $233,634.00. Following the sale, the insider now owns 105,479 shares in the company, valued at approximately $5,357,278.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jared Watkin sold 552 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total value of $26,479.44. Following the sale, the insider now owns 47,090 shares in the company, valued at approximately $2,258,907.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 218,702 shares of company stock worth $10,149,733. Corporate insiders own 0.76% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.